Hana A.
- Country
- Germany
- Department
- Medical Oncology Department
Research Overview
- Phase 1/2 Open‑Label Study of VS‑7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and Combination Therapy in Patients with Advanced KRAS G12D‑Mutant Solid Tumors
- Phase 3 Randomized Trial of Daraxonrasib Monotherapy or Daraxonrasib + Gemcitabine/Nab‑Paclitaxel vs Gemcitabine/Nab‑Paclitaxel in First‑Line Metastatic Pancreatic Cancer
- Phase 3 Randomized Study of Tucatinib, Trastuzumab, and mFOLFOX6 vs. mFOLFOX6 with Cetuximab or Bevacizumab in HER2+ Metastatic Colorectal Cancer
Data & Insights
Has run more than one trial at 48 of 176 partner sites.
Specializations
Pancreatic Cancer Research
This investigator specializes in the treatment of pancreatic ductal adenocarcinoma (PDAC), with particular emphasis on both metastatic and resected disease states.
- Metastatic PDAC Treatment
- Post-surgical Adjuvant Therapy
- Novel Therapeutic Combinations
Their research extends to various treatment approaches for pancreatic cancer patients, including chemotherapy combinations and targeted therapies.
Treatment Innovation
The investigator explores innovative therapeutic strategies involving targeted agents and combination therapies for pancreatic cancer treatment.
- First-line Therapy Development
- Maintenance Treatment Strategies
- Immunotherapy Applications
Their work encompasses both conventional chemotherapy optimization and novel therapeutic agent integration.
Clinical Outcomes
The investigator focuses on measuring critical clinical endpoints in pancreatic cancer treatment, including survival metrics and therapeutic efficacy.
- Overall Survival Assessment
- Disease-free Survival Evaluation
- Safety and Tolerability Studies
Their research emphasizes comprehensive evaluation of treatment outcomes in various disease stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.